indicates PN20K has the potential to significantly impact cardiovascular diseases because of its ability to change chemical and physical characteristics of blood, providing a "one-two punch." "We simply don't see these positive effects with typical pharmaceutical drugs," says Dr. Holsworth.
In Japan, the enzyme has an annual 15 billion yen market. Since its introduction to the U.S. market, bulk sales for the enzyme have experienced increased growth and demand. With different manufacturers of nattokinase from all over the world, the activity, stability and purity of the product varies significantly. NZymeCeuticals' bulk ingredients undergo third-party testing for quality assurance and quality control as well as to preserving the integrity of the new ingredient. Clinical research using PN20K as the therapeutic agent is well underway.
http://www.nzymeceuticals.com
###
Read the full story at http://www.prweb.com/releases/nattokinase/holsworth/prweb1294934.htm
'/>"/>Source: PRWeb Copyright©2008 Vocus, Inc. All rights reserved | |
Page: 1 2 Related medicine news :1.
HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services2.
Z Trim Holdings, Inc. Announces Private Placement Funding3.
The Risk Management and Patient Safety Institute Announces Agreement With Pioneering Health Care Simulation Organization, PSO One4.
Cogdell Spencer Announces First Synergy Project in Pensacola, Florida5.
Conde Nast Media Group Announces Performance of Just Stand Up to be Fed Live from the Stage at FASHION ROCKS to ABC, CBS and NBCs Simultaneous Broadcast of Stand Up To Cancer Nationwide Fund-Raising Event On September 5th6.
LIFE Foundation Announces 2008 realLIFEstories Award Recipients to Illustrate Benefits of Life and Disability Insurance7.
Elbit Imaging Ltd. Announces Second Quarter Results for 20088.
Custom Briefings Announces Launch of Endocrine Daily Briefing9.
Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss10.
Versus Technology Announces Third Quarter Results11.
Replidyne Announces Restructuring of Operations